Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Aclaris Therapeutics ( (ACRS) ).
Aclaris Therapeutics has secured an exclusive license agreement with Biosion for global rights to promising biologics targeting immuno-inflammatory diseases. This move not only broadens Aclaris’ drug pipeline but also strengthens its financial position with an $80 million private placement. The leadership team has been bolstered with the addition of experienced biotech executives, aiming to advance innovative therapies for patients. The company is set for strategic growth, supported by a strong R&D engine and an enhanced cash runway extending to 2028.
See more data about ACRS stock on TipRanks’ Stock Analysis page.
